温和女人 发表于 2025-3-23 10:47:20

https://doi.org/10.1007/978-3-642-24070-6liferative signals. Although imatinib is an effective frontline therapy that has provided a remarkable success in the treatment of CML, the resistance to the inhibitor is still an obstacle. Quiescent leukemic stem cells are unresponsive to imatinib. BCR-ABL-dependent and BCR-ABL-independent mechanis

mastopexy 发表于 2025-3-23 14:38:31

http://reply.papertrans.cn/23/2250/224970/224970_12.png

EWE 发表于 2025-3-23 18:13:05

http://reply.papertrans.cn/23/2250/224970/224970_13.png

RAGE 发表于 2025-3-24 02:14:53

Harald Atmanspacher,Thomas Filkntional chemotherapy for patients with relapsed/refractory ALL showed better objective response. This review summarizes the clinical efficacy and safety of INO in the treatment of relapsed/refractory ALL, based on currently available data in the literature.

Blasphemy 发表于 2025-3-24 04:36:56

http://reply.papertrans.cn/23/2250/224970/224970_15.png

窝转脊椎动物 发表于 2025-3-24 08:26:16

http://reply.papertrans.cn/23/2250/224970/224970_16.png

招待 发表于 2025-3-24 11:29:45

https://doi.org/10.1007/978-3-642-25316-4y in both untreated APL patients and relapsed patients who have been treated with ATRA and chemotherapy. Retinoids are a model of the development of new molecular-targeted agents for other malignant tumors.

凹槽 发表于 2025-3-24 17:35:29

http://reply.papertrans.cn/23/2250/224970/224970_18.png

obsolete 发表于 2025-3-24 20:32:52

http://reply.papertrans.cn/23/2250/224970/224970_19.png

BARB 发表于 2025-3-25 01:28:48

http://reply.papertrans.cn/23/2250/224970/224970_20.png
页: 1 [2] 3 4 5 6
查看完整版本: Titlebook: Chemotherapy for Leukemia; Novel Drugs and Trea Takanori Ueda Book 2017 Springer Nature Singapore Pte Ltd. 2017 Acute promyelocytic leukemi